Qingdong Qiao
Overview
Explore the profile of Qingdong Qiao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang R, Qiao Q, Yang D, Zhang J, Zhu C, Sun J, et al.
Urolithiasis
. 2022 Jan;
50(2):205-214.
PMID: 35075494
To evaluate the efficacy and safety of the use of Ningmitai capsule as an adjunctive stone expulsion therapy after RIRS. All patients were diagnosed with upper urinary tract calculi measuring...
2.
Wang L, Li H, Qiao Q, Ge Y, Ma L, Wang Q
Aging (Albany NY)
. 2020 Nov;
12(21):21674-21686.
PMID: 33176280
Bladder cancer (BC) is one of the most commonly diagnosed urologic carcinomas, with high recurrence and death rates. Circular RNAs (circRNAs) are a class of noncoding RNAs which are anomalously...
3.
Li J, Qiao Q, Zhuang J, Wang C
Se Pu
. 2016 Jul;
34(2):170-5.
PMID: 27382722
An analytical method was developed to simultaneously determine the residues of four β2-agonists in animal foods by high performance liquid chromatography/electrospray-tandem mass spectrometry (HPLC-MS/MS). Samples were extracted with 5% (mass...
4.
Wang L, Ma L, Wang X, Li B, Guo S, Qiao Q
Int J Clin Exp Pathol
. 2015 Oct;
8(8):9397-403.
PMID: 26464694
Background: Early prostate cancer antigen 2 (EPCA-2), a kind of nuclear matrix protein, may relate to prostate cancer. However, the association of EPCA-2 level in serum with prostate diseases has...
5.
Wang L, Ma L, Wang X, Li B, Guo S, Qiao Q
Int Urol Nephrol
. 2015 Feb;
47(4):617-24.
PMID: 25686740
Purpose: To compare the therapeutic effects and adverse events (AE) of current first-line treatments of advanced RCC, including sorafenib, sunitinib, temsirolimus, and the combination of bevacizumab and IFN-α. Methods: We...